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Abstract
Introduction: The complement system is crucial for the development of antineutrophil cytoplasmic antibody
(ANCA)-associated vasculitis (AAV). In particular, C5a plays a central role. In this study, plasma and urinary levels of
C5a as well as renal C5a receptors (CD88 and C5L2) expression were investigated in patients with AAV.
Methods: Twenty-four patients with AAV in the active phase, 19 patients with AAV in the remission phase, and 20
patients with lupus nephritis (LN) were included. Plasma and urinary levels of C5a were measured with enzyme-
linked immunosorbent assay (ELISA). The staining of CD88 and C5L2 in renal specimens was detected with
immunohistochemistry.
Results: The level of plasma C5a was significantly higher in patients with AAV in the active phase than that in
patients in remission, that in patients with LN, and that in normal controls. The urinary C5a level was significantly
higher in patients with AAV in the active phase than that in patients in remission and that in normal controls, but
not significantly different between patients with active AAV and patients with LN. The mean optical density of
CD88 staining in the tubulointerstitium was significantly lower in AAV patients than that in normal controls (0.0052
± 0.0011 versus 0.029 ± 0.0042; P = 0.005). The mean optical density of C5L2 in glomeruli was significantly higher
in AAV patients than that in normal controls (0.013 ± 0.0027 versus 0.0032 ± 0.0006; P < 0.001). The mean optical
density of CD88 staining closely correlated with the initial eGFR (r = 0.835; P < 0.001) in AAV patients. Double-
labeling immunofluorescence assay suggested that CD88 did not express on neutrophils, monocytes, or
macrophages, but C5L2 expressed on neutrophils (or monocytes) and macrophages.
Conclusion: The elevated plasma and urinary C5a levels indicated complement activation in human AAV. The level
of renal CD88 expression could reflect the disease severity of ANCA-associated glomerulonephritis. CD88 expression
was downregulated, and C5L2 was upregulated in ANCA-associated glomerulonephritis.
Introduction
Antineutrophil cytoplasmic antibodies (ANCAs)-asso-
ciated vasculitis (AAV) comprises a group of autoim-
mune disorders, including granulomatosis with
polyangiitis (GPA, previously named Wegener granulo-
matosis), microscopic polyangiitis (MPA), Churg-Strauss
syndrome (CSS), and renal-limited vasculitis (RLV) [1].
These diseases are characterized by necrotizing small-
vessel vasculitis. ANCAs are the serologic hallmarks for
the previously mentioned primary small-vessel vasculitis.
ANCAs are predominantly immunoglobulin G (IgG)
autoantibodies directed against neutrophil cytoplasmic
constituents, in particular, proteinase 3 (PR3) and mye-
loperoxidase (MPO) [1].
The histopathologic hallmark of ANCA-associated
glomerulonephritis is “pauci-immune” necrotizing cres-
centic glomerulonephritis (NCGN), characterized by lit-
tle or no glomerular staining for immunoglobulins and
complements in renal histology by immunofluorescence
microscopy examination. Recent studies in a mouse
model of anti-MPO IgG-mediated glomerulonephritis
suggested that complement activation via the alternative
pathway was crucial for the disease development [2,3].
In particular, Schreiber et al. [4] further found that
recombinant C5a dose-dependently primes neutrophils
for an ANCA-induced respiratory burst. In animal mod-
els, C5a receptor (C5aR)-deficient animals were
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protected from ANCA-induced NCGN. As such, the
interaction between C5a and C5aR (CD88) may com-
pose an amplification loop and, thus, plays a central role
in ANCA-mediated neutrophil recruitment and activa-
tion [4]. However, the role of interaction between C5a
and its receptors in the pathogenesis of human AAV is
less clear.
C5a is a cleavage product of complement C5 with
chemotactic and anaphylatoxic properties. C5a exerts its
action through two different receptors: C5aR (CD88)
and C5a receptor-like 2 (C5L2), each of which can bind
C5a with high affinity [5]. CD88 contributes to the
initiation of acute inflammatory responses, such as che-
motaxis, enzyme release, and the respiratory burst [5,6].
In contrast, C5L2 seems to have antiinflammatory func-
tions by reducing the C5a available binding to CD88, so
it is called a “default” or “scavenger” receptor [5,6].
However, the role of C5L2 is much more unclear and is
inconsistent in different diseases [7]. It has been
reported that C5L2 is implicated in the inflammatory
response in ovalbumin-induced asthma [7]. To the best
of our knowledge, C5L2 has not been investigated in
AAV. In the current study, plasma and urinary levels of
C5a as well as renal C5a receptors (CD88 and C5L2)




Twenty-four consecutive patients with AAV in the
active phase of initial onset before initiation of immuno-
suppressive therapy and 19 consecutive patients with
AAV in the remission phase after immunosuppressive
therapy, diagnosed at Peking University First Hospital
from 2008 to 2009, were included. All these patients
had a positive test for perinuclear ANCA (P-ANCA) by
indirect immunofluorescence and MPO-ANCA by anti-
gen-specific enzyme-linked immunosorbent assay
(ELISA). All these patients met the Chapel Hill Consen-
sus Conference (CHCC) definition of AAV [8] and had
complete clinical data. All the previously mentioned 24
patients with AAV in the active phase received renal
biopsy at diagnosis and before immunosuppressive ther-
apy. “Remission” was defined as “absence of disease
activity attributable to active disease qualified by the
need for ongoing stable maintenance immunosuppres-
sive therapy” (complete remission), or “50% reduction of
disease activity score and absence of new manifesta-
tions” (partial remission), as described previously [9].
Patients with secondary vasculitis or with any other
coexisting renal disease were excluded.
Twenty-five age- and gender-matched healthy blood
donors and 20 patients with biopsy-proven lupus
nephritis (LN), diagnosed in the same period in our
center, were enrolled as normal control and disease con-
trol, respectively. All the patients with lupus nephritis
fulfilled the 1997 American College of Rheumatology
revised criteria for systemic lupus erythematosus (SLE)
[10]. Of the 20 patients with lupus nephritis, six were
classified as type III, and 14 were classified as type IV,
according to the abbreviated version of the ISN/RPS
classification [11].
Estimated glomerular filtration rate (eGFR) was calcu-
lated by using the modification of diet in renal disease
(MDRD) equations [12].
The research was in compliance of the Declaration of
Helsinki and approved by the ethics committee of our
hospital. Written informed consent was obtained from
each participant.
Plasma and urine samples collection
For patients with AAV in the active phase and patients
with lupus nephritis, blood and urinary samples were
collected at the day of renal biopsy and before the initia-
tion of immunosuppressive treatment. For patients with
AAV in the remission phase, blood samples were col-
lected at their regular ambulatory visits. Peripheral
blood was collected by using disodium EDTA as antic-
oagulant, and plasma was collected after centrifugation.
The plasma and urine samples were immediately put on
ice after the sample was drawn to prevent complement
degradation ex vivo. After centrifugation, all the samples
were stored in aliquots at -80°C until use. When testing,
after rapid thawing at 37°C, the frozen specimens were
transferred immediately in ice before use within 1 hour.
The specimens were tested without repeated freeze and
thaw.
Isolation of neutrophils
Neutrophils were isolated from heparinized venous
blood of healthy donors by density gradient centrifuga-
tion on Lymphoprep (Nycomed, Oslo, Norway). Ery-
throcytes were lysed with ice-cold ammonium chloride
buffer, and neutrophils were washed in Hanks balanced
salt solution without Ca2+/Mg2+ (HBSS-/-; Chemical
Reagents, Beijing, China). Neutrophils were then sus-
pended in HBSS with Ca2+/Mg2+(HBSS+/+; Chemical
Reagents) to a concentration of 2.5 × 106 cells/ml. Neu-
trophils were activated by 2 ng/ml tumor necrosis factor
(TNF)-a. The specimens were fixed with 70% ethanol
for 5 minutes, and permeabilized with 0.5% Triton X-
100 for 5 minutes at 4°C.
Quantification of C5a
Urine and plasma concentrations of human fragment
C5a were determined with enzyme-linked immunoassays
(Quidel Corporation, San Diego, CA, USA). Optimal
dilutions of urine and plasma samples were obtained
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according to the ELISA kit instructions. The urinary
creatinine also was measured. The urinary level of C5a
was calculated by the ratio of urinary concentration of
C5a to the urinary creatinine.
Renal histology
The renal histology of patients with AAV in the active
phase was evaluated according to the previous standar-
dized protocol [13-15]. The presence of glomerular
lesions, including fibrinoid necrosis, crescents, and glo-
merulosclerosis, was calculated as the percentage of the
total number of glomeruli in a biopsy. Interstitial and
tubular lesions were scored semiquantitatively on the
basis of the percentage of the tubulointerstitial compart-
ment that was affected: interstitial infiltrate ("-"for 0; “+”
for 0 to 20%; “++” for 20% to 50%; and “+++” for >
50%), interstitial fibrosis ("-” for 0; “+” for 0 to 50%; and
“++"for > 50%) and tubular atrophy ("-” for 0; “+” for 0
to 50%; and “++” for > 50%).
In renal sections stained with hematoxylin/eosin (HE),
the numbers of neutrophils were counted in the glomer-
uli of AAV by an experienced pathologist.
Renal immunohistochemistry
Five renal tissues were obtained from the normal part of
nephrectomized (because of renal carcinoma) kidneys
and were used as normal controls. Their renal tissues
were considered normal with light microscopy, immu-
nofluorescence, and electron microscopy.
Tissue sections were deparaffinized in xylene and
rehydrated through grading alcohols. Slides were
immersed in citric acid buffer (0.01 M, pH 6.0) and
were treated in an 800 W microwave oven for 2 minutes
and then at 200 W for 8 minutes, for antigen retrieval.
Slides were rinsed in phosphate-buffered saline (0.01%
PBS). Endogenous peroxidase was blocked with 0.3%
H2O2 in methanol for 30 minutes at room temperature.
After a 30-minute blocking step with 3% normal goat
serum diluted in PBS, mouse anti-human CD88 (1:50
dilution; Abcam, Cambridge, UK; catalog number,
ab11867), rabbit anti-human C5L2 (1:500 dilution;
Abcam, catalog number, ab77982), and mouse anti-
human CD66b (1:200 dilution; Abnova, Taiwan; catalog
number, MAB7198) were applied and incubated over-
night at 4°C in a moisture chamber. After multiple PBS
rinses, the slides were exposed to secondary antibodies.
The detection system used, Dako EnVision HRP (Dako
A/S, Copenhagen, Denmark), was an avidin-free two-
step indirect method with goat anti-rabbit and goat
anti-mouse immunoglobulins conjugated with horserad-
ish peroxidase (HRP) as secondary antibodies. The sec-
ondary antibodies were incubated for 30 minutes at 37°
C, and sections were developed in fresh hydrogen per-
oxide plus 3-3-diaminobenzidine tetrahydrochloride
solution for 1 minute. As negative controls, primary
antibodies were replaced by normal rabbit IgG or nor-
mal mouse IgG. Finally, the sections were incubated
with hematoxylin and dehydrated through alcohols and
xylene. The sections were examined with light
microscopy.
In total, 20 fields of vision per kidney section (three to
four sections per kidney) at ×200 were observed blindly
as a semiquantitive assessment of immunohistochemical
staining. The renal CD88 and C5L2 stainings were eval-
uated with the Image Pro Plus analysis software 6.0. The
positive signals were quantified as the mean optical den-
sity (integrated option density/area).
Colocalization of CD88 as well as C5L2 with elastase and
CD68
Elastase is the marker for neutrophils and monocytes [16],
and CD68 is the marker for macrophages [17]. Colocaliza-
tion of CD88 and C5L2 with elastase and CD68 was
judged by double-labeling immunofluorescence in forma-
lin-fixed paraffin-embedded tissue. The deparaffinage and
antigen-retrieval step were consistent with the previous
immunohistochemistry described earlier. After a 30-min-
ute blocking step with 3% normal goat serum diluted in
PBS, mouse anti-human CD88 (1:5 dilution; Abcam) com-
bined with rabbit anti-human neutrophil elastase (1:50
dilution; Abcam) or with rabbit anti-human CD68 (1:50
dilution; Abbiotec, San Diego, CA, USA), and rabbit anti-
human C5L2 (1:50 dilution; Abcam) combined with
mouse anti-human neutrophil elastase (1:5 dilution; Gen-
way Biotech, San Diego, CA, USA) or with mouse anti-
human CD68 (1:5 dilution; Abcam) were added and incu-
bated overnight at 4°C in a moisture chamber, 3 × 5-min-
ute washes in PBS. The secondary antibodies FITC-labeled
goat anti-mouse IgG and TRITC-labeled goat anti-rabbit
IgG (both 1:60; Southern Biotech) were incubated for 30
minutes at 37°C in a moisture chamber, 3 × 5-minute
washes in PBS. Nuclei were stained with DAPI (ZSGB,
Beijing, China) and sections mounted with Citifluor. In
negative controls, primary antibodies were replaced by
normal rabbit IgG or normal mouse IgG.
The spleen and neutrophils were used as positive con-
trols. Neutrophils were isolated from peripheral blood of
healthy blood donors and fixed with 70% ethanol. The
spleen tissues were obtained from a patient subjected to
splenectomy for traumatic splenic rupture. The spleen
tissues were fixed in 10% buffered formalin, processed
through graded alcohols and xylene, and embedded in
paraffin. For the primary antibody, mouse anti-human
CD88 (1:20 dilution for neutrophil-coated slides and 1:5
dilution for spleen tissues; Abcam) combined with rabbit
anti-human neutrophil elastase (1:50 dilution for neutro-
phils and spleen; Abcam) were used. The other steps
were consistent with aforementioned method.
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The stained sections were visualized with fluorescence
microscopy (80i; Nikon, Tokyo, Japan). Images were
exported from the Nikon fluorescence microscopy
software.
Hematoxylin/eosin and CD88 counterstaining
To confirm whether CD88 was expressed on renal infil-
trated neutrophils of AAV patients, the renal sections of
AAV were counterstained with HE on the basis of
immmunohistochemical staining of CD88 (1:50 dilution;
Abcam; catalog number, ab11867). The sections were
examined with light microscopy.
Statistical analysis
Differences of quantitative parameters between groups
were assessed by using the t test (for normally distribu-
ted data) or nonparametric test (for non-normally dis-
tributed data). Spearman correlation was used to
measure the relation between two non-normally distrib-
uted variables or between one non-normally distributed
variable and one normally distributed variable. Pearson
correlation was used to measure the relation between
two normally distributed variables. The difference was
considered significant if the P value was < 0.05. Analysis
was performed with the SPSS statistical software pack-
age (version 13; Chicago, IL, USA).
Results
Demographic and clinical data
Among the 24 patients with AAV in the acute phase, 11
were male and 13 were female patients, with an age of
55.4 ± 15.7 years (range, 14 to 82 years) at diagnosis. Of
the 24 patients, the level of initial serum creatinine was
297.0 ± 232.8 (range, 59 to 1,007) μM; the level of urin-
ary protein excretion was 2.56 ± 1.72 g/24 hours (range,
0.23 to 7.35 g/24 hours). Twenty patients had renal
insufficiency at diagnosis. The organ involvements are
listed in Table 1.
Among the 19 patients with AAV in the remission
phase, nine were male and 10 were female patients, with
an age of 62.1 ± 13.9 years (range, 30 to 81 years) at
diagnosis. The level of serum creatinine was 165.3 ±
99.3 (range, 58 to 441) μM. The level of Birmingham
Vasculitis Activity Scores [18] (BVAS) was 0 and 2 in 18
and one patients, respectively.
Renal histopathology
Among the renal biopsies of the 24 patients with the
active phase of AAV, all had little or no staining for
IgG, IgA, and IgM by immunofluorescence microscopy
(≤ 1+ on a scale of 0 to 4+). No or little electron-
dense deposit was detected with electron microscopy.
The glomerular and tubulointerstitial lesions are listed
in Table 2.
We found 2.56 ± 0.14 neutrophils per glomeruli of
AAV in HE staining sections, whereas no neutrophils
were present in glomeruli of normal controls (see Addi-
tional file 1, Figure S1).
Plasma and urinary C5a levels
Plasma samples were obtained from 24 patients with
AAV in the active phase, 19 patients with AAV in the
remission phase, 20 patients with LN, and 25 healthy
blood donors. Urinary levels of C5a were measured in
24 patients with AAV in the active phase, 19 patients




Average age at onset of the disease (years) 55.364 ± 15.72
Serum creatinine (SCr; μM)
Mean ± SD 296.99 ± 232.83
Range 59 to 1,007
eGFR (ml/min/1.73 m2)
Mean ± SD 31.98 ± 31.48
Range 0.7 to 118
Renal insufficiency at diagnosis 20 (83.3%)
Urinary protein (g/24 hours)
Mean ± SD 2.56 ± 1.72
Range 0.23 to 7.35
Skin rash 2 (8.3%)
Arthralgia 8 (33.3%)





Nervous system 2 (8.3%)
BVAS 20.46 ± 4.93
BVAS, Birmingham Vasculitis Activity Score; eGFR, estimated glomerular
filtration rate; ENT, ear, nose, and throat; SD, standard deviation.
Table 2 Renal histopathology of patients with ANCA-
associated vasculitis
Glomerular lesions Percentage
Normal glomeruli 37.90 ± 37.40
Crescents 62.09 ± 31.69
Cellular crescents 16.39 ± 16.52
Fibrocellular crescents 33.66 ± 24.43
Fibrous crescents 12.04 ± 20.00
Glomerular sclerosis (median and range) 5.26 (0 to 30.0)
Tubulointerstitial lesions Number
Interstitial infiltration (-/+/++/+++) 1/4/4/15
Interstitial fibrosis (-/+/++) 1/8/15
Tubular atrophy (-/+/++) 1/7/16
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with AAV in remission, 10 patients with LN, and 25
healthy blood donors.
The level of plasma C5a was significantly higher in
patients with AAV in the active phase than that in
patients with AAV in remission, patients with LN, and
normal controls (75.67 ± 11.93 ng/ml versus 8.78 ± 1.12
ng/ml; P < 0.001; 75.67 ± 11.93 ng/ml versus 30.42 ±
4.07 ng/ml; P < 0.001; 75.67 ± 11.93 ng/ml versus 7.37
± 0.90 ng/ml; P < 0.001, respectively). No significant dif-
ferences in C5a levels were found between normal con-
trol and patients with AAV in remission (8.78 ± 1.12
ng/ml versus 7.37 ± 0.90 ng/ml; P = 0.887) (Figure 1).
The urinary C5a level was significantly higher in
patients with AAV in the active phase than that in
patients with AAV in remission and normal controls
(3.00 ± 0.78 ng/ml versus 0.18 ± 0.044 ng/ml, P < 0.001;
3.00 ± 0.78 ng/ml versus 0.13 ± 0.02 ng/ml, P < 0.001,
respectively). This was also the case after adjustment for
urinary creatinine (14.13 ± 3.54 ng/mg Cr versus 0.023
± 0.0058 ng/mg Cr; P < 0.001; 14.13 ± 3.54 ng/mg Cr
versus 0.0246 ± 0.0037 ng/mg Cr; P < 0.001, respec-
tively). No significant difference was noted in urinary
C5a levels between patients with AAV in the active
phase and patients with LN (Figure 1). No significant
correlation was found between the levels of plasma C5a
and urinary C5a in patients with AAV.
Immunohistochemistry for CD88, C5L2, and CD66b
Studies on renal histopathology were performed in
patients with AAV in the active phase. In renal speci-
mens of patients with AAV, immunohistochemical
examination revealed prominent expression of CD88 in
Figure 1 Plasma and urinary levels of C5a. The horizontal lines in the graph represent the mean values. (A) Plasma level of C5a. (B) Urinary
level of C5a. (C) Urinary level of C5a adjusted for urinary creatinine. AAV, ANCA-associated vasculitis; LN, lupus nephritis.
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proximal tubules, distal tubules, and collecting ducts.
Expression of CD88 protein was scanty in glomeruli and
vasculature of the normal controls and in the patients
with AAV (Figure 2).
In contrast, expression of C5L2 was detected in the
glomeruli and vasculature. The positive staining of C5L2
was also seen in proximal tubules, distal tubules, collect-
ing ducts, and interstitium (Figure 2).
Figure 2 Immunohistochemistry for CD88 and C5L2 in renal specimens. (Glomeruli, magnification ×400; tubulointerstitium, magnification
×200; vasculature, magnification ×400).
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Immunohistochemical examination showed the promi-
nent expression of CD66b, which is an ideal marker for
neutrophils, in glomeruli of AAV patients. Expression of
CD66b was scanty in the glomeruli of normal controls
(see Additional file 2, Figure S2). It indicated that a
number of neutrophils were present in the glomeruli of
AAV patients, but no or few neutrophils in the glomer-
uli of normal controls.
CD88 and C5L2 staining in renal specimens were
evaluated by the Image Pro Plus analysis software (ver-
sion 6.0; Dallas, TX, USA). The mean optical density of
CD88 in patients with AAV in the tubulointerstitium
was significantly lower than that in normal controls
(0.0052 ± 0.0011 versus 0.029 ± 0.0042; P = 0.005). The
mean optical density of C5L2 in glomeruli was signifi-
cantly higher in patients with AAV than that in normal
controls (0.013 ± 0.0027 versus 0.0032 ± 0.0006; P <
0.001). However, no significant difference was seen for
the mean optical density of C5L2 in the tubulointersti-
tium between patients with AAV and normal controls
(0.034 ± 0.005 versus 0.044 ± 0.006; P = 0.227).
Among the patients with AAV, correlation analysis
showed that the mean optical density of CD88 corre-
lated with initial eGFR (r = 0.835; P < 0.001), and inver-
sely correlated with initial serum creatinine (r = -0.628;
P < 0.001). The mean optical density of CD88 in
patients with interstitial infiltrate greater than 50% was
significantly lower than that in those with interstitial
infiltrate ≤ 50% (0.0035 ± 0.0008 versus 0.0070 ±
0.0023; P = 0.034).
The mean density of glomerular C5L2 staining corre-
lated with the ratio of glomerular cell number to glo-
merular area (r = 0.561; P = 0.004).
Immunofluorescence double-labeling
By using immunofluorescence double-labeling with neu-
trophil elastase or CD68, we determined whether CD88
and C5L2 was expressed on neutrophils (or monocytes)
or macrophages. It was shown that little or no CD88
was expressed on neutrophils, monocytes, or macro-
phages in renal specimens of patients with AAV, and
this result was proved by two other anti-CD88 monoclo-
nal antibodies (Santa Cruz Biotechnology, catalog num-
ber sc-70812, and Abcam, catalog number ab11884, (see
Additional files 3, 4, 5, and 6, Figures S3, S4, S5, and
S6). However, CD88 could colocalize with elastase in
the spleen- and neutrophil-coated slides. C5L2 expres-
sion partly colocalized with neutrophils (or monocytes)
and macrophages (Figures 3 and 4).
HE and CD88 counterstaining
On the basis of immmunohistochemical staining of
CD88, the renal sections of AAV were counterstained
with HE. Little or no CD88 staining was noted in renal
infiltrated neutrophils (see Additional file 7, Figure S7).
This was consistent with the results of immunofluores-
cence double-labeling of CD88 and elastase.
Discussion
It was previously assumed that the complement system
was not involved in the pathogenesis of AAV, because
little immunoglobulin or complement deposition is
found in AAV, and AAV is generally not associated
with hypocomplementemia [19,20]. However, increasing
evidence suggests that activation of the complement sys-
tem, via the alternative pathway, is crucial for the devel-
opment of AAV [2-4,15,21-23]. The complement system
comprises more than 30 plasma and membrane-bound
proteins. Among these proteins, C5a, together with its
receptor, seems to play a central role in the pathogen-
esis of AAV, demonstrated by both animal and in vitro
studies [4]. The current study further investigated C5a
as well as its receptor, CD88 and C5L2, in human AAV.
In the current study, only patients with positive MPO-
ANCA were included, for two reasons. First, previous
studies that investigated the role of the complement sys-
tem in the pathogenesis of AAV focused mainly on
MPO-ANCA-positive vasculitis [2-4,15]. Second, our
previous studies suggested that MPO is the most impor-
tant ANCA target antigen for Chinese patients with
AAV; MPO-ANCA-positive patients constituted about
80% to 90% of Chinese patients with AAV [20,24-26].
In the current study, we investigated the plasma and
urinary levels of C5a. The potent anaphylatoxin, C5a, is
released when C5 is cleaved by C5 convertase [27]. The
measurement of cleavage products such as C5a in
plasma, therefore, can provide a sensitive index of com-
plement activation. It was found that the plasma level of
C5a was about 10 times higher in patients with AAV in
the active phase than that in normal controls. In the
remission phase of AAV, the plasma level of C5a was
comparable to that of normal controls. It might indicate
an especially important role of C5a in AAV, compared
with some other autoimmune diseases, such as primary
antiphospholipid syndrome, in which plasma level of
C5a is normal [22]. The urinary level of C5a, after
adjustment for urinary creatinine, was even higher
(about 560 times) in patients with AAV than that in
normal controls. Our results confirmed and further
extended a recent observation [28]. Increased urinary
C5a might come from two sources. First, C5a may
derive from the circulation because of glomerular base-
ment membrane damage. Second, the complement may
be activated locally in kidneys, and C5a is therefore
released to urine [29,30]. Overall, it may indicate the
pathogenic role of excessive or uncontrolled production
of C5a in AAV, in particular, in the glomerulonephritis
of AAV.
Yuan et al. Arthritis Research & Therapy 2012, 14:R140
http://arthritis-research.com/content/14/3/R140
Page 7 of 12
Figure 3 Colocalization of C5a receptors (CD88 and C5L2) and elastase. (A) Colocalization of CD88 and elastase in glomeruli (arrowheads).
(B) Colocalization of CD88 and elastase in tubulointerstitium (arrowheads). (C) Colocalization of C5L2 and elastase in tubulointerstitium
(arrowheads). (D) Colocalization of CD88 and elastase in the spleen. (E) Colocalization of CD88 and elastase in resting neutrophils. (F)
Colocalization of CD88 and elastase in activated neutrophils. Magnification ×400.
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The two types of C5a receptors, CD88 and C5L2, both
have high affinity for C5a [6]. Although in vitro studies
have found that mesangial cells could express CD88
[31], the current study demonstrated that CD88 is
expressed mainly in proximal tubules, distal tubules, and
collecting ducts, but scarcely at all expressed in glomer-
uli and vasculature in patients with AAV. Our results
are in line with those of previous studies [32-34].
The expression of CD88 in the patients with AAV was
significantly lower than that in normal controls, and,
more important, was closely correlated with renal func-
tion and the extent of interstitial infiltration. Moreover,
double-labeling immunofluorescence demonstrated that
CD88 is scanty on neutrophils, monocytes, and macro-
phages. In a different opinion, CD88 is expressed in
myeloid cells and is unable to be detected in tubular
epithelial cells [35]. However, in the current study,
CD88 staining was confirmed by two other anti-CD88
monoclonal antibodies, and similar results were
obtained (see Additional files 3, 4, 5, 6, and Figures S3,
S4, S5, S6). Moreover, in positive controls, neutrophils
could be stained by anti-CD88 monoclonal antibodies.
Therefore, our results on neutrophil CD88 staining are
reliable.
To confirm that the small amount of glomerular
CD88 in AAV patients was not because of the lack of
neutrophils in the glomeruli, neutrophils in the glomer-
uli of AAV patients were confirmed by both HE staining
and immunohistochemical staining of CD66b (see Addi-
tional file 1, Figure S1; Additional file 2, Figure S2).
Obviously, more neutrophil infiltration was found in the
renal section of AAV patients than in normal controls.
Immunohistochemical examination showed prominent
expression of CD66b in glomeruli of AAV patients,
whereas expression of CD66b was scanty in glomeruli of
normal controls. Moreover, in HE and CD88
Figure 4 Colocalization of C5a receptors (CD88 and C5L2) and macrophages. (A) Colocalization of CD88 and CD68 in glomeruli
(arrowheads). (B) Colocalization of CD88 and CD68 in tubulointerstitium (arrowheads). (C) Colocalization of C5L2 and CD68 in glomeruli
(arrowheads). (D) Colocalization of C5L2 and CD68 in tubulointerstitium (arrowheads). Magnification ×400.
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counterstaining, little or no CD88 staining was noted in
renal infiltrated neutrophils (see Additional file 7, Figure
S7). Therefore, it was clear that the small amount of
CD88 in glomeruli of AAV patients was because neutro-
phils in the glomeruli “lost” CD88, not because of the
lack of neutrophils in the glomeruli.
Schreiber et al. [4] suggested that CD88 in cells of
myeloid origin plays a crucial role in the development of
AAV. It is well known that CD88 on neutrophils inter-
acts with C5a to produce a series of functional
responses such as chemotaxis, enzyme release, degranu-
lation, and respiratory burst [6]. All of these functions
induce inflammatory responses and are involved in
ANCA-mediated tissue damage [4]. However, the pre-
cise role of CD88 in renal tubular epithelial cells in
AAV patients remains less defined. In the renal ische-
mia-reperfusion injury model, the interaction between
C5a and CD88 on tubular epithelial cells induces a local
inflammatory response resulting in cellular dysfunction
and leads to renal function loss [36]. CD88 is known to
be rapidly internalized after treatment with C5a [37].
The low expression of CD88 in AAV patients might be
attributed to C5a-mediated internalization. The downre-
gulation of CD88 expression in AAV patients might
contribute to the self-protection mechanism, so as to
alleviate the C5a-mediated inflammation. We speculate
that binding of C5a to the CD88 in renal tubular epithe-
lial cells may also be involved in tubulointerstitial injury
in AAV patients. In AAV, the role of CD88 expression
in the tubulointerstitium and the mediators responsible
for downregulation of CD88 expression in the tubuloin-
terstitium await further studies.
In contrast, the role of C5L2 remains controversial.
C5L2 has been shown to be a nonsignaling decoy recep-
tor and to compete with CD88 for binding to C5a.
Thereby, C5L2 attenuates the proinflammatory C5a
response. However, a study demonstrated that C5L2 is
involved in the pathogenesis of asthma-like airway
hyperresponsiveness and inflammation [7]. Thus, C5L2
plays complex and dual roles in the pathogenesis of
inflammation. To the best of our knowledge, the current
study was the first one to investigate C5L2 in AAV. We
found that the expression of C5L2 in glomeruli in AAV
patients is significantly higher than that in normal con-
trols. In ANCA-associated glomerulonephritis, glomeru-
lar intrinsic cells proliferation was not common. To
some extent, the increase of cells in the glomerular tuft
can reflect the glomerular inflammatory infiltrate. In our
study, the expression of C5L2 in glomeruli positively
correlated with the numbers of cells in the glomeruli.
Moreover, C5L2 also expressed on neutrophils (or
monocytes) and macrophages, besides on renal intrinsic
cells. The significantly increased expression of C5L2 in
renal specimens suggested that expression of C5L2 is
regulated differently from that of CD88 in AAV. Unlike
CD88, C5L2 did not show internalization on C5a bind-
ing [38]. Moreover, inflammatory cells (that is, neutro-
phils, monocytes, and macrophages) infiltrated in
kidneys could enhance the C5L2 expression. Whether
C5L2 participated in proinflammatory or antiinflamma-
tory responses in AAV requires further study.
Conclusions
In conclusion, the elevated plasma and urinary C5a
levels indicated complement activation in human AAV.
The level of renal CD88 expression could reflect the dis-
ease severity of ANCA-associated glomerulonephritis.
CD88 expression was downregulated, and C5L2 was
upregulated in ANCA-associated glomerulonephritis.
The exact mechanism of the regulation of CD88 and
C5L2 in AAV requires further study.
Additional material
Additional file 1: Figure S1. HE staining in renal sections of AAV
Neutrophils, arrowheads. Magnification, ×400.
Additional file 2: Figure S2. Immmunohistochemical staining of CD66b.
(A) Immmunohistochemical staining of CD66b in renal sections of AAV.
Arrowheads, CD66b-positive cells. (B) Immmunohistochemical staining of
CD66b in renal sections of normal controls. (C) Immmunohistochemical
staining of CD66b in spleen. Magnification, ×400.
Additional file 3: Figure S3. Colocalization of CD88 and elastase in
renal specimens. (A) Colocalization of CD88 and elastase by Abcam
antibody (catalog number, ab11884) (arrowheads). (B) Colocalization of
CD88 and elastase by Santa Cruz antibody (catalog number, sc-70812)
(arrowheads). Magnification, ×400.
Additional file 4: Figure S4. Colocalization of CD88 and elastase in the
spleen. (A) Colocalization of CD88 stained by Abcam antibody (catalog
number, ab11884) and elastase in the spleen (B) Colocalization of CD88
stained by Santa Cruz antibody (catalog number, sc-70812) and elastase
in the spleen. Magnification, ×400.
Additional file 5: Figure S5. Co-localization of CD88 and elastase in
neutrophil-coated slides. (A) Colocalization of CD88 and elastase in
resting neutrophils by Abcam antibody (catalog number, ab11884). (B)
Colocalization of CD88 and elastase in activated neutrophils by Abcam
antibody (catalog number, ab11884). (C) Colocalization of CD88 and
elastase in resting neutrophils by Santa Cruz antibody (catalog number,
sc-70812). (D) Colocalization of CD88 and elastase in activated
neutrophils by Santa Cruz antibody (catalog number, sc-70812).
Magnification, ×400.
Additional file 6: Figure S6. Immmunohistochemical staining of CD88
in spleen. (A) Immmunohistochemical staining of CD88 in spleen by
Abcam antibody (catalog number, ab11867). (B) Immmunohistochemical
staining of CD88 in spleen by Abcam antibody (catalog number,
ab11884). (C) Immmunohistochemical staining of CD88 in spleen by
Santa Cruz antibody (catalog number, sc-70812).
Additional file 7: Figure S7. Hematoxylin/eosin (HE) and CD88
counterstaining. CD88, open arrow; neutrophils, solid arrow.
Magnification, ×400.
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